Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis

Diabetes and Metabolism

Volumn 38, Issue 6, 2012, Pages 475-484

  Colmers, I N ^a   Bowker, S L ^a   Johnson, J A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Meta analysis; Pharmacoepidemiology; Pioglitazone; Review; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

BIBLIOGRAPHIC DATABASE; BILE DUCT CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; COLORECTAL CANCER; DIABETIC PATIENT; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE TUMOR; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; META ANALYSIS; MOUTH CANCER; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT DURATION; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 84870685371     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.06.003     Document Type: Review

References (51)

1. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010, 47:87-95.
2. Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol 2009, 5:651-652.
3. Johnson J.A., Bowker S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011, 54:25-31.
4. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
5. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
6. Canadian Diabetes Association Clinical Practice Guidelines. Can J Diabetes 2008, 32:1-215.
7. Giannini S., Serio M., Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004, 27:982-991.
8. Burton J.D., Goldenberg D.M., Blumenthal R.D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008, 2008:1-7.
9. Perez-Ortiz J., Llorens S., Llopis J., Tranque P., Nava E. Potential benefits of glitazones for cancer and vascular disease. Curr Drug Ther 2008, 3:111-125.
10. Fogo A.B. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Curr Opin Nephrol Hypertens 2008, 17:282-285.
11. Belfiore A., Genua M., Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res 2009, 2009:1-18.
12. Pioglitazone hydrochloride in treating patients with stage I, stage II, or stage III non-small cell lung cancer [Internet]. Available from: http://clinicaltrials.gov/ct2/show/. Access1st edn0 May 2012. ctgov:NCT01342770.
13. The impact of obesity and obesity treatments on breast cancer [Internet]. Available from: http://clinicaltrials.gov/ct2/show/. Access10th edn May 2012. ctgov:NCT00933309.
14. Rosiglitazone (Avandia) vs. placebo for androgen dependent prostate cancer [Internet]. Available from: http://clinicaltrials.gov/ct2/show/. Accessed 10 May 2012. ctgov:NCT00182052.
15. Colmers I.N., Bowker S.L., Majumdar S.R., Johnson J.A. Thiazolidindione use and risk of bladder cancer in type 2 diabetes: a systematic review and meta-analysis. CMAJ 2012, in press.
16. Ferrara A., Lewis J.D., Quesenberry C.P., Peng T., Strom B.L., Van Den Eeden S.K., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34:923-929.
17. Govindarajan R., Ratnasinghe L., Simmons D.L., Siegel E.R., Midathada M.V., Kim L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 25:1476-1481.
18. Koro C., Barrett S., Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007, 16:485-492.
19. Lewis J.D., Capra A.M., Achacoso N.S., Ferrara A., Levin T.R., Quesenberry C.P., et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology 2008, 135:1914-1923. 1923.e1.
20. Higgins J., Altman D. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews 2008, John Wiley & Sons, Ltd., Chichester UK. J. Higgins, S. Green (Eds.).
21. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis [Internet]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10 May 2012.
22. Papanikolaou P.N., Christidi G.D., Ioannidis J.P.A. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006, 174:635-641.
23. Ioannidis J.P.A., Mulrow C.D., Goodman S.N. Adverse events: the more you search, the more you find. Ann Intern Med 2006, 144:298-300.
24. Golder S., Loke Y.K., Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011, 8:e1001026.
25. Mittmann N., Liu B.A., Knowles S.R., Shear N.H. Meta-analysis and adverse drug reactions. CMAJ 1999, 160:987-988.
26. Mannucci E., Monami M., Balzi D., Cresci B., Pala L., Melani C., et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010, 33:1997-2003.
27. Yang X., So W.Y., Ma R.C.W., Yu L.W.Y., Ko G.T.C., Kong A.P.S., et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010, 90:343-351.
28. Higgins J., Altman D. Including non-randomized trials. Cochrane Handbook of Systematic Reviews of Interventions 2008, John Wiley & Sons, Ltd., Chichester, UK. J. Higgins, S. Green (Eds.).
29. Higgins J., Altman D. Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions 2008, John Wiley & Sons, Ltd., Chichester, UK. J. Higgins, S. Green (Eds.).
30. Dormandy J.A., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
31. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006, 355:2427-2443.
32. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
33. Insulin glargine injection treatment in place of thiazolidinedione (TZD), sulfonylurea, or metformin in triple agent therapy for type 2 diabetes mellitus (T2DM) subjects with unsatisfactory control [Internet]. Available from: http://clinicaltrials.gov/ct2/show/. Accessed 10 May 2012. ctgov:NCT00283049.
34. CNAMTS. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI [Internet]. Available from: http://www.afssaps.fr/var/afssaps_site/storage/original/application/b42a6bf9a1b63c3dbec7388d3914687b.pdf. Accessed 10 Maa 2012.
35. Oliveria S.A., Koro C., Ulcickas Yood M., Sowell M. Cancer incidence among patients treated with antidiabetic therapy. Diabetes Metab Syndrome: Clin Res Rev 2008, 2:45-57.
36. Tseng C.H. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011, 34:616-621.
37. Zhang H-T, Hammad TA, Christiani D, Giovannucci E. The risk of cancer associated with anti-diabetic agents. Abstracts of the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Providence, Rhode Island, USA. August 16-19, 2009 [Abstract].
38. Bodmer M., Meier C., Krähenbühl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
39. El-Serag H.B., Hachem C., Johnson M.L., Morgan R.O. Insulin treatment and risk of hepatocellular carcinoma in patients with diabetes. Gastroenterology 2009, 136. A-126.
40. Hassan M.M., Curley S.A., Li D., Kaseb A., Davila M., Abdalla E.K., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116:1938-1946.
41. Li D., Yeung S.C.J., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
42. Long M., Vinikoor L., Martin C., Galanko J., Keku T., Sandler R. Thiazolidinedione use and rectal cancer in diabetics: a population based case-control study. Am J Gastroenterol 2008, 103:S387. [Abstract].
43. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009, 20:1617-1622.
44. Home P.D., Kahn S.E., Jones N.P., Noronha D., Beck-Nielsen H., Viberti G., et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone evaluated for cardiovascular outcomes and regulation of glycaemia in diabetes) clinical trials. Diabetologia 2010, 53:1838-1845.
45. Carstensen B. Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage With the risk of cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry. Diabetes;59:1254-1260. Diabetes 2010;59:e17.
46. Bennett W.L., Maruthur N.M., Singh S., Segal J.B., Wilson L.M., Chatterjee R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
47. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
48. Alves C., Batel-Marques F., Macedo A.F. Data sources on drug safety evaluation: a review of recent published meta-analyses. Pharmacoepidemiol Drug Saf 2012, 21:21-33.
49. Chou R., Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005, 142:1090-1099.
50. Inzucchi S.E., Sherwin R.S. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2005, 34:199-219.
51. Johnson J., Carstensen B., Witte D., Bowker S., Lipscombe L., Renehan A. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012, 55:1607-1618.